The life sciences and healthcare industries should restructure around patient centricity, according to global not-for-profit the Pistoia Alliance.
The call follows a meeting at the Pistoia Alliance’s annual European conference in London where discussions around the sector’s position in the wake of the Covid-19 pandemic took place. Attendees at the meeting highlighted how advances in technology are helping patients become more empowered regarding their health. The Pistoia Alliance is now calling for greater collaboration between links in the biopharmaceutical value chain to support and advance this shift and ensure that patient centricity is embedded right from early discovery to healthcare delivery.
At the meeting, attendees debated the structural and operational changes required around patient centricity in drug development. One area that emerged is the need to listen closely to patients and work alongside them. This includes adjusting the language and terminology used to refer to people living with diseases and to shape new initiatives around engagement and involvement. Attendees also discussed the pressing need to maintain an open attitude to gathering and sharing data that can be applied to improve outcomes. This ranged from digital monitoring of patients, designing clinical trial protocols that reduce patient burden, sharing data with both co-researchers and patients, gathering more data on rare diseases, and employing data to drive AI and machine learning.
In a keynote address at the meeting, Cristina Ortega Duran, Chief Digital Health Officer R&D for AstraZeneca said: “We are living through the largest transformation in human history. Technology is growing exponentially and that’s difficult to comprehend. Change doesn’t happen at the pace of technology development. Industries take a longer time to change than technology because changing behaviour is much harder. But the pandemic has changed behaviours. Billions of people changed the way they interact with healthcare in a matter of months. In this new era of targeted precision medicine, we all play a role in creating the patient-centric future that patients deserve.”
To facilitate the urgent restructuring of the life science industry around patients, the sector must build on the rapid progress that has been made in digital healthcare during the global pandemic and translate this success to early phase R&D. This will mean collaborating with patient groups to learn their concerns and preferences and ensure the therapies that make it to market suit their needs and are affordable.
Panellist Thomas Hach, Executive Director Patient Engagement Cardiovascular, Renal & Metabolism, Novartis, added: “Patients will be the biggest disruptors in health care, now and in the future. We better listen to them, and really listen to them. We need to show the impact and the value that data generates for participants in a trial, and we have to do that early. Because sometimes we do that too late, and we can’t properly take the advice of patients. Let’s have the people living with the disease push us and challenge us because that’s how we make research better. In the end, we want to achieve something together. And together, it’s always better.”
Thierry Escudier, a Strategic Theme Lead at the Pistoia Alliance, said: “In the last two years we’ve witnessed huge advances in digital healthcare, now we must take what we have learned and apply this mindset to early phase R&D and clinical settings, where there is plenty of work for us to do. We must close the gap between researchers and data scientists working on target selection, and patients actually living with the condition. By putting patients at the heart of our work from “day one”, we can deliver better therapeutics and improve patient outcomes. Our projects at the Pistoia Alliance will offer opportunity for biopharmaceutical organisations and R-LPOs to work directly together in support of this aim.”